ClinicalTrials.Veeva

Menu

Spinal Morphine and Atropine Added to General Anaesthesia for Nausea and Pain After Abdominal Laparoscopy

U

Universitas Indonesia

Status and phase

Completed
Phase 4

Conditions

Postoperative Pain
Laparoscopy
Anesthesia Spinal
Postoperative Nausea and Vomiting
Anesthesia

Treatments

Drug: Intrathecal bupivacaine, morphine and atropine
Procedure: General anaesthesia
Drug: Multimodal analgesia and antiemetic prophylaxis

Study type

Interventional

Funder types

Other

Identifiers

NCT07851870
2106795356

Details and patient eligibility

About

Laparoscopic abdominal surgery carries one of the highest risks of postoperative nausea and vomiting (PONV), and postoperative opioids given for pain are themselves emetogenic. Intrathecal morphine provides prolonged analgesia but increases nausea; intrathecal atropine 100 µg has been reported to reduce morphine-related nausea under spinal anaesthesia alone, but has not been tested within a combined spinal-general technique.

This randomised, open-label, parallel-group trial compared combined spinal-general anaesthesia (CSGA), hyperbaric bupivacaine 10 mg, morphine 100 µg and atropine 100 µg given intrathecally before induction, followed by general anaesthesia, with general anaesthesia (GA) alone in adults undergoing elective abdominal laparoscopy. Both groups received identical general anaesthesia, multimodal analgesia (paracetamol and ketorolac at skin closure), end-of-case ondansetron and neostigmine-atropine reversal.

The primary outcome was the occurrence of PONV within 24 hours after surgery. Secondary outcomes were postoperative pain, rescue antiemetic and rescue opioid requirements, intraoperative fentanyl consumption and perioperative haemodynamics.

Full description

summarise Methods: setting, randomisation by computer-generated sequence, spinal technique at L4-5 with 27-G Quincke needle, target T6 block, induction and maintenance regimen, assessment schedule at 1, 2, 6, 12 and 24 h, sample size assumptions of 75% vs 40% PONV at α 0.05 and 80% power, per-protocol analysis.

Enrollment

63 patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged 18 to 64 years
  • ASA physical status I or II
  • Body mass index 30 kg/m² or less
  • Scheduled for elective digestive, gynaecological or urological laparoscopy
  • Written informed consent given

Exclusion criteria

  • Uncontrolled stage 2 hypertension
  • Heart failure, arrhythmia, valvular heart disease or atrioventricular block
  • Cerebrovascular event within the previous 3 months
  • Raised intracranial pressure
  • Severe renal or hepatic disease
  • Coagulopathy
  • Infection at the site of lumbar puncture

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

63 participants in 2 patient groups

Combined spinal-general anaesthesia (CSGA)
Experimental group
Description:
Before induction, spinal anaesthesia at L4-5 in the sitting position with a 27-G Quincke needle: 0.5% hyperbaric bupivacaine 10 mg, preservative-free morphine 100 µg and atropine sulphate 100 µg, made up to 4 mL with 0.9% saline, targeting a T6 sensory level. General anaesthesia was then induced and maintained as in the comparator arm.
Treatment:
Drug: Multimodal analgesia and antiemetic prophylaxis
Procedure: General anaesthesia
Drug: Intrathecal bupivacaine, morphine and atropine
GA alone
Active Comparator group
Description:
General anaesthesia without any neuraxial block: induction with lidocaine 1.5 mg/kg, fentanyl 2 µg/kg, propofol 2 mg/kg and rocuronium 0.6 mg/kg; maintenance with sevoflurane in oxygen-air at target MAC 0.8, with fentanyl 25-50 µg boluses for haemodynamic response.
Treatment:
Drug: Multimodal analgesia and antiemetic prophylaxis
Procedure: General anaesthesia

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems